Global Blood Therapeutics (GBT) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
GBT Reports Second Quarter 2021 Financial Results
August 3, 2021 4:05 PM EDTAchieved Oxbryta® (voxelotor) net revenues of $47.6 million, an increase of 51% year-over-year
Continued progress toward potential Oxbryta pediatric label expansion in U.S. and marketing authorization in Europe  Â
Advanced pipeline with initiation of two inclacumab pivotal Phase 3 trials and GBT021601 (GBT601) Phase 1 trial  Conference call today at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported financial results for the second quarter ended June 30, 2021 and... More
